Project co-funded by CDTI and FEDER

Date: 2019-01-30 by Canvax
Project co-funded by CDTI and FEDER

CAR-T Therapy has shown an unprecedented success in the treatment of Hematological Tumors. In order to develop an Universal CAR-T based in own technology, Canvax Biotech has executed the project «Dymorphic and Universal CAR-T for Cancer Immunotherapy, Infectious and Autoimmune Diseases».

This project has been co-funded by CDTI and Fondo Europeo de Desarrollo Regional (FEDER) with the aim of promoting technological development, innovation and quality research, within the framework of the State Plan for Scientific and Technical Research and Innovation 2017- 2020, for a total amount of 693,929€.